Related posts

Oil climbs, stocks moderately move13 Recession-Proof Stocks for Portfolio SafetyFlat Wednesday
Investor Insights

This summary was created by AI, based on 15 opinions in the last 12 months.

Experts have mixed opinions about Abbott Labs. While some praise its diversified business across pharmaceuticals, medical devices, and nutrition, others express concerns about ongoing lawsuits related to their baby formula. Despite these legal challenges, the company has shown strong financials, with consistent growth in both top and bottom lines. Overall, Abbott Labs is seen as a solid company with potential for growth, especially due to its resilient device business and positive outlook for the future.

Consensus
Mixed
Valuation
Fair Value
HOLD
Abbott Labs

Pharma companies are always facing the patent wall, needing to spend R&D to innovate new drugs. Very difficult to predict the next blockbuster. He prefers and owns JNJ and ABT, as they're more diversified.

biotechnology / pharmaceutical
BUY
Abbott Labs

Has excellent fundamentals across four businesses, including best-in-class medical devices renown in cardiology. However, they face lawsuits over their similac formula which studies show is not harmful. It's unfair. It lost a lawsuit last summer and was hit a $495 million penalty. More lawsuits are coming, though the latest decision yesterday went in Abbott's favour. Last month, federal agencies found that the formula is not at fault. Two weeks ago, ABT reported a clean top and bottom line beat and raised their full-year forecast. Shares would have rallied more without the lawsuits.

biotechnology / pharmaceutical
PAST TOP PICK
Abbott Labs
(A Top Pick Oct 23/23, Up 25%)

Expects it to growth topline and bottom line going forward, usually around the 10% range. Sells branded generic drugs to EMs, medical devices, infant nutrition. Diabetes monitoring product has very good growth. Likes that it's diversified, well managed. Yield close to 3%, grown for over 50 consecutive years.

biotechnology / pharmaceutical
BUY
Abbott Labs

His favourite in this sector. They just delivered a monster quarter.

biotechnology / pharmaceutical
COMMENT
Abbott Labs

They report Wednesday. Are facing legal challenges that their baby formula kills, but last week the FDA and CDC cleared them. This could turn the tide.

biotechnology / pharmaceutical
BUY
Abbott Labs

They're turning around, given their immunotherapy pipeline, and their device and testing businesses are strong.

biotechnology / pharmaceutical
TOP PICK
Abbott Labs

Pharma is challenged on growth, whereas devices have robust growth. Its device business has grown exceptionally well, between 10-12% organically. Overhang has been unfavourable comparisons from Covid testing. Reasonable valuation for quite a good company. Yield is 2%.

(Analysts’ price target is $123.65)
biotechnology / pharmaceutical
COMMENT
Abbott Labs

They lost a major court case last Friday and have to pay nearly $500 million in damages over its formula for premature babies. He feels the verdict is an outrage. Their formula saves lives and doctors recommend it.

biotechnology / pharmaceutical
BUY ON WEAKNESS
Abbott Labs

They report on July 18. The company is doing very well, but they could lose a looming lawsuit. He wouldn't add more shares unless this breaks below $100.

biotechnology / pharmaceutical
BUY
Abbott Labs

Outlook is fabulous. Recent lawsuits turning out fine. Would buy at $100/share. 

biotechnology / pharmaceutical
HOLD
Abbott Labs

Diversified businesses in medical devices, testing technology, pharma, nutrition. Selling off as a result of $60M judgement against competitor's infant formula, worries of contagion. Long-term, it will work out. 

biotechnology / pharmaceutical
PAST TOP PICK
Abbott Labs
(A Top Pick Apr 20/23, Down 2%)

Flat over the year. Wonderful product portfolio. Structural driver is heart/cardiac business. Reported yesterday, topline growth 2%. This number is misleading, as cardiac organic growth was 14%, and organic growth outside of diagnostics was 10%. Performing well, growing quite well, reasonable multiple. He'd buy today.

biotechnology / pharmaceutical
BUY
Abbott Labs
To enter a new position

Yes, buy. Almost always they report and the reaction is negative at first, then it recovers. BTW, they had an excellent quarter.

biotechnology / pharmaceutical
BUY ON WEAKNESS
Abbott Labs

They report Wednesday. Usually, shares climb after the report, then someone finds fault with a single line item, then shares fall. Buy on the dip the next day.

biotechnology / pharmaceutical
BUY
Abbott Labs

Likes healthcare in general, a larger weight for him. Chart's performing pretty decently relative to the S&P 500. Could give nice returns going forward. 

biotechnology / pharmaceutical
Showing 1 to 15 of 195 entries

Abbott Labs(ABT-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 10

Neutral - Hold Signals / Votes : 2

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 12

Stockchase rating for Abbott Labs is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Abbott Labs(ABT-N) Frequently Asked Questions

What is Abbott Labs stock symbol?

Abbott Labs is a American stock, trading under the symbol ABT-N on the New York Stock Exchange (ABT). It is usually referred to as NYSE:ABT or ABT-N

Is Abbott Labs a buy or a sell?

In the last year, 12 stock analysts published opinions about ABT-N. 10 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Abbott Labs.

Is Abbott Labs a good investment or a top pick?

Abbott Labs was recommended as a Top Pick by on . Read the latest stock experts ratings for Abbott Labs.

Why is Abbott Labs stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Abbott Labs worth watching?

12 stock analysts on Stockchase covered Abbott Labs In the last year. It is a trending stock that is worth watching.

What is Abbott Labs stock price?

On 2024-12-10, Abbott Labs (ABT-N) stock closed at a price of $115.5.